Role of transforming growth factor-β1 in prostate cancer

Microscopy Research and Technique

Volumn 52, Issue 4, 2001, Pages 411-419

  Wikström, Pernilla ^a   Damber, Jan Erik ^b   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Immunosuppression; Metastasis; Regulation of prostatic growth; TGF 1

Indexed keywords

CANCER CELLS; CELL DEATH; DIAGNOSIS; DISEASES; PATHOLOGY; TUMORS; UROLOGY;

ANGIOGENESIS; EPITHELIAL CELLS; IMMUNOSUPPRESSION; METASTASIS; PROSTATE CANCER CELLS; PROSTATE CANCERS; PROSTATE TUMOR; REGULATION OF PROSTATIC GROWTH; TGF-Β; TGF-Β1;

CELL PROLIFERATION;

ANDROGEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; APOPTOSIS; CANCER GROWTH; CYTOKINE RELEASE; EPITHELIUM CELL; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

EID: 0035865274     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8     Document Type: Review

References (107)

1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. 1999. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 161:182-187.
2. Ananth S, Knebelmann B, Griming W, Dhanabal M, Walz G, Stillman IE, Sukhatme VP. 1999. Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59:2210-2216.
3. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. 1993. Anti-transforming growth factor (tgf)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host tgf-beta interactions in human breast cancer p. J Clin Invest 92:2569-2576.
4. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. 1983. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258:7155-7160.
5. Boyle P, Maisonneuve P, Napalkov P. 1995. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 46:47-55.
6. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M. 1999. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 59:2731-2738.
7. Chang I-L, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. 1993. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of meth sarcoma cells. Cancer Res 53:4391-4398.
8. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. 1992. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267:19027-19030.
9. Chu TM, Kawinski E. 1998. Plasmin, substilisin-like endoproteases, tissue plasminogen activator, and urokinase plasminogen activator are involved in activation of latent TGF-β 1 in human seminal plasma. Biochem Biophys Res Commun 253:128-134.
10. Chung LWK, Davies R. 1996. Prostate epithelial differentiation is dictated by its surrounding stroma. Mol Biol Rep 23:13-19.
11. Cipriano SC, Chen YQ. 1998. Insensitivity to growth inhibition by TGF-β1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. Oncogene 17:1549-1556.
12. Contractor HE, Barrack ER, Breul J. 1994. Potential role of T-lyphocytes in prostate tumor growth enhancement by transforming growth factor beta1 (TGFβ1). J Urol 151:366A.
13. Danielpour D. 1999. Transdifferention of NRP-152 prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-β. J Cell Sci 112:169-179.
14. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB. 1994. Development and characterization of non-tumorigenic and tumorigenic epithelial cell lines from rat dorso-lateral prostate. Cancer Res 54:3413-3421.
15. de Visser KE, Kast WM. 1999. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 13: 1188-1199.
16. Denmeade SR, Xiaohui SL, Isaacs JT. 1996. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28:251-265.
17. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. 1995. Transforming growth factor-β1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73:628-635.
18. English HF, Santen RJ, Isaacs JT. 1987. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11:229-242.
19. Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D, Teti A. 1999. Osteoblast conditioned media contain TGF-β1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 81:395-403.
20. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M. 1993. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846-1856.
21. Gann PH, Klein KG, Chatterton RT, Ellman AH, Grayhack JT, Nadler RB, Lee C. 1999. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates. Prostate 40:248-255.
22. Gerdes MJ, Dang TD, Larsen M, Rowley DR. 1998. Transforming growth factor-β1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology 139:3569-3577.
23. Gleave M, Hsieh J, Gao C, Von Eschenbach A, Chung LWK. 1991. Acceleration of human prostate cancer cell growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761.
24. Go C, Li P, Wang XJ. 1999. Blocking transforming growth factor b signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res 59:2861-2868.
25. Gohongi T, Fukumura D, Boucher Y, Yun CO, Soff GA, Compton C, Todoroki T, Jain RK. 1999. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor β1. Nat Med 5:1203-1208.
26. Guo Y, Kyprianou N. 1998. Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 9:185-193.
27. Gou Y, Kyprianou N. 1999. Restoration of transforming growth factor b signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1 mediated apoptosis. Cancer Res 15:1366-1371.
28. Guo Y, Jacobs SC, Kyprianou N. 1997. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in human prostate cancer. Int J Cancer 71:573-579.
29. Hahn SA, Schutte M, Hoque A, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21. Science 271:350-353.
30. Hartsough MT, Mulder KM. 1997. Transforming growth factor-β signaling in epithelial cells. Pharmacol Ther 75:21-41.
31. Heldin C-H, Miyazono K, ten Dijke P. 1997. TGF-β signalling from cell to nucleus through SMAD proteins. Nature 390:465-471.
32. Hocevar BA, Howe PH. 1998. Mechanisms of TGF-β-induced cell cycle arrest. Miner Electrolyte Metab 24:131-135.
33. Hsing AY, Kadomatsu K, Bonham MJ, Danielpour D. 1996. Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res 56:5146-5149.
34. Huggins C, Stevens REJ, Hodges CV. 1941. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate. Arch Surg 43:209-223.
35. Hwa V, Oh Y, Rosenfeld RG. 1997. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3. Endocrine 6:235-242.
36. Ilio KY, Sensibar JA, Lee C. 1995. Effect of TGF-β1, TGF-α and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J Androl 16:482-490.
37. Isaacs JT. 1984. Antagonistic effect of androgen on prostatic cell death. Prostate 5:545-557.
38. Itoh N, Patel U, Cupp AS, Skinner MK. 1998. Developmental and hormonal regulation of transforming growth factor-β1 (TGFβ1), -2, and -3 gene expression in isolated prostatic epithelial and stromal cells: epidermal growth factor and TGFβ interactions. Endocrinology 139:1378-1388.
39. Jensen OM, Esteve J, Moller H, Renard H. 1990. Cancer in the European Community and its Member States [published erratum appears in Eur J Cancer 1991;27:1717] [see comments]. Eur J Cancer 26:1167-1256.
40. Kassen A, Sutkowski DM, Ahn H, Sensibar JA, Kozlowski JM, Lee C. 1996. Stromal cells of the human prostate: initial isolation and caracterization. Prostate 28:89-97.
41. Kerr JFR, Searle JW. 1973. Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch B Cell Pathol 13:87-102.
42. Kim IY, Ahn H-J, Zelner DJ, Park L, Sensibar JA, Lee C. 1996a. Expression and localization of transforming growth factor-β receptors type I and type II in the rat ventral prostate during regression. Mol Endocrinol 10:107-115.
43. Kim IY, Ahn H-J, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein, MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. 1996b. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissue. Clin Cancer Res 2:1255-1261.
44. Kim IY, Ahn H-J, Zelner JW, Shaw JA, Sensibar JA, Kim J-H, Kato M, Lee C. 1996c. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 56:44-48.
45. Kim IY, Ahn H-J, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, Lee C. 1998. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 4:1625-1630.
46. Kingsley DM. 1994. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8:133-146.
47. Koeneman KS, Yeung F, Chung LW. 1999. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246-261.
48. Kyprianou N, Isaacs JT. 1988a. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology 123:2124-2131.
49. Kyprianou N, Isaccs JT. 1988b. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562.
50. Kyprianou N, Isaacs JT. 1989. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515-1522.
51. Kyprianou N, English HF, Isaacs JT. 1990. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753.
52. Landström M, Eklöv S, Colosetti P, Nilsson S, Damber J-E, Bergh A, Funa K. 1996. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-β1 and its type-I and type-II receptors. Int J Cancer 67:573-579.
53. Lee C. 1996. Role of androgen in prostate growth and regression: stromal-epithelial interaction. Prostate Suppl 6:52-56.
54. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, Cho JS, Ilio KY, Cronauer MV, Janulis L, Sensibar JA. 1999. Transforming growth factor-β in benign and malignant prostate. Prostate 39:285-290.
55. Lindström P, Bergh A, Holm I, Damber J-E. 1996. Expression of TGF-β1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment. Prostate 29:209-218.
56. López-Casillas F, Wrana JL, Massagué J. 1993. Betaglycan presents ligand to the TGFβ signaling receptor. Cell 73:1435-1444.
57. Martikainen P, Kyprianou N, Isaacs JT. 1990. Effect of transforming growth factor-beta1 on proliferation and death of rat prostatic cells. Endocrinology 127:2963-2968.
58. Marushige K, Marushige Y. 1994. Induction of apoptosis by transforming growth factor β1 in glioma and trigeminal neurinoma cells. Anticancer Res 14:2419-2424.
59. Massagué J. 1990. The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641.
60. Mathews E, Yang T, Janulis L, Goodwin S, Kundu S, Lee C. 1999. Down regulation of TGF-β1 production restores immunogenicity in Dunning's rat prostate cancer cells (MatLyLu). Proceedings of the 1999 EUSOE Meeting, Paris: 46(P).
61. McKeehan WL, Adams PS. 1988. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta. In Vitro Cell Dev Biol 24:243-246.
62. Miyazono K, Hellman U, Wernstedt C, Heldin C-H. 1988. Latent high molecular weight complex of transforming growth β1: purification from human platelets and structural characterization. J Biol Chem 263:6407-6415.
63. Miyazono K, ten Dijke P, Ichijo H, Heldin C-H. 1994. Receptors for transforming growth factor-β. Adv Immunol 55:181-220.
64. Morton DM, Barrack ER. 1995. Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55:2596-2602.
65. Munger JS, Harpel JG, Gleizes P-E, Mazzieri R, Nunes I, Rifkin DB. 1997. Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int 51:1376-1382.
66. Nemeth JA, Lee C. 1996. Prostatic ductal system in rats: regional variation in morphological and functional activities. Prostate 232: 124-128.
67. Nemeth JA, Sensibar JA, Lee C. 1995. Changes in TGF-β localization in the rat prostatic ductal system during castration-induced regression. Proceedings 77th Annual Meeting for the Endocrine Society, Washington, DC, June 14-17, 1995.
68. Nemeth JA, Sensibar JA, White RR, Zelner DJ, Kim IY, Lee C. 1997. Prostatic ductal system in rats: tissue-specific expression and regional variation in stromal distribution of transforming growth factor-β 1. Prostate 33:64-71.
69. Nishi N, Oya H, Matsumoto K, Nakamura T, Miyanaka H, Wada F. 1996. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. Prostate 28:139-152.
70. Oberhammer F, Bursch W, Tiefenbacher R, Fröschl G, Pavelka M, Purchio T, Schulte-Hermann R. 1993. Apoptosis is induced by transforming growth factor-beta I within 5 hours in regressing liver without significant fragmentation of the DNA. Hepatology 18: 1238-1245.
71. Peehl DM, Sellers RG. 1997. Induction of smooth muscle cell phenotypes in cultured human prostatic cells. Exp Cell Res 232:208-215.
72. Petros JA, Andriole GL. 1993. Serum PSA after antiandrogen therapy. Urol Clin North Am 20:749-756.
73. Rajah R, Valentinis B, Cohen P. 1997. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188.
74. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. 1996. Mad-related genes in the human. Nat Genet 13:347-349.
75. Robson CN, Gnanapragasam V, Byrne RL, Collins AT, Neal DE. 1999. Transforming growth factor-β1 up-regulates p15, p21, and p27 and blocks cell cycling in G1 in human prostate epithelium. Endocrinology 160:257-266.
76. Robson H, Anderson E, James RD, Schofield PF. 1996. Transforming growth factor β1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74:753-758.
77. Rorke EA, Jacobberger JW. 1995. Transforming growth factor-beta 1 (tgf beta 1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells. Exp Cell Res 216:65-72.
78. Rotello RJ, Liebermann RC, Purchio AF, Gerschenson LE. 1991. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor âin cultured murine epithelial cells. Proc Natl Acad Sci USA 88:3412-3415.
79. Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. 1998. Transforming growth factor β1 and its receptors. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Growth Factors 16:101-110.
80. Russell PJ, Bennet S, Stricker P. 1998. Growth factor involvement in progression of prostate cancer. Clin Chem 44:705-723.
81. Sogani PC, Fair WR. 1987. Treatment of advanced prostatic cancer. Urol Clin North Am 14:353-371.
82. Stattin P, Westin P, Damber J-E, Bergh A. 1998. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer 77:670-675.
83. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. 1999. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Canc Res 5:711-720.
84. Steiner MS. 1996. Peptide growth factors in prostate cancer: a focus on transforming growth factor-β1. AUA News 5-10.
85. Steiner MS, Barrack ER. 1992. Transforming growth factor-beta1 overproduction in prostate cancer: effects of growth in vivo and in vitro. Mol Endocrinol 6:15-25.
86. Steiner MS, Zhou Z-Z, Tonb DC, Barrack ER. 1994. Expression of transforming growth factor-beta I in prostate cancer. Endocrinology 13:2240-2247.
87. Steiner MS, Anthony CT, Metts J, Moses H. 1995. Prostate cancer cells lose their sensitivity to TGFβ1 growth inhibition with tumor progression. Urol Oncol 1:252-262.
88. Story MT, Hopp KA, Meier DA, Begun FP, Lawson RK. 1993. Influence of transforming growth factor-beta I and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. Prostate 22: 183-197.
89. Sun L, Wu G, Willson JKV, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang X-F, Brattain MG. 1994. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269:26449-26455.
90. Sutkowski DM, Fong C-J, Sensibar JA, Rademaker ED, Sherwood ER, Kozlowski JE, Lee C. 1992. Interaction of epidermal growth factor and transforming growth factor β in human prostatic epithelial cells in culture. Prostate 21:133-143.
91. Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Bottinger EP, Danielpour D, Wakefield LM. 1999. Loss of responsiveness to transforming growth factor β induces malignant transformation of non-tumorigenic rat prostate epithelial cells. Cancer Res 50:4834-4842.
92. Teatle R, Payne C, Dos Santos B, Russell M, Segarini P. 1993. Effects of transforming growth factor β1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res 53:3386-3393.
93. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. 1992. Transforming growth factor beta1 as a biomarker for prostate cancer. J Cell Biochem 16H:54-61.
94. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. 1994. Mesenchymal-epithelial interactions and transforming growth factor beta expression during mouse prostate morphogenesis. Endocrinology 134:1039-1045.
95. Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. 1995. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol 13:324-328.
96. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. 1993. Association of transforming growth factor beta1 with prostate cancer: an immunohistochemical study. Hum Pathol 24:4-9.
97. Wang J, Sun LZ, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JKW, Brattain MG. 1995. Demonstration that mutation of the type II transforming growth factor b receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270: 22044-22049.
98. Wang X-F, Lin HY, NG-Eaton E, Downward J, Lodish HF, Weinberg RA. 1991. Expression cloning and characterization of the TGF-β type III receptor. Cell 67:797-805.
99. Westin P, Stattin P, Damber J-E, Bergh A. 1995. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146: 1368-1375.
100. Wikström P, Stattin P, Franck-Lissbrant I, Damber J-E, Bergh A. 1998. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37:19-29.
101. Wikström P, Lindh G, Bergh A, Damber J-E. 1999a. Alterations of transforming growth factor β1 (TGF-β1) and TGFβ receptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines. Urol Res 27: 185-193.
102. Wikström P, Westin P, Stattin P, Damber J-E, Bergh A. 1999b. Early castration induced upregulation of transforming growth factor β1 and its receptors is associated with tumour cell apoptosis and a major decline in serum prostate specific antigen in prostate cancer patients. Prostate 38: 268-277.
103. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. 1989. Differential effects of transforming growth factor β on human prostate cell lines in vitro. Mol Cell Endocrinol 62:79-87.
104. Williams RH, Stapleton AMF, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. 1996. Reduced levels of transforming growth factor b receptor type II in human prostate cancer: an immunohistochemical study. Clinical cancer research 2:635-640.
105. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. 1994. Mechanism of activation of the TGF-β receptor. Nature 370:341-347.
106. Wu HS, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LWK. 1994. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57:406-412.
107. Yanagihara K, Tsumuraya M. 1992. Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 52:4042-4045.